 Home > Active Ingredient News > Antitumor Therapy > JITC: Breakthrough!

JITC: Breakthrough!

 Last Update: 2022-08-19
 Source: Internet
 Author: User

Tags

study time space

drugs take seroquel

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In a new study, researchers from Tel Aviv University in Israel and the University of Lisbon in Portugal have discovered and synthesized a small molecule that could become an easier target than an antibody that has been successfully used to treat a range of cancers Obtained, more efficient alternative.

Professor Satchi-Fainaro said, “In 2018, the Nobel Prize in Medicine was awarded to James Allison and Tasuku Honjo for their contributions to the study of immunotherapy – the treatment of cancer by activating the immune syste.

Antibodies against PD-1/PD-L1 proteins have been approved for clinical use and are considered a great hope in the fight against cance.

In silico virtual screening of potential PD-1/PD-L1 inhibitor.

Professor Satchi-Fainaro said, "Postdoctoral researcher D.

In addition to drug accessibility considerations, the authors' experiments showed that the small-molecule drug improved the activation of immune cells within solid tumor masse.

Professor Satchi-Fainaro explained, "The surface of solid tumors is heterogeneou.

References:

Rita .

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Best Quality 99.9% Ruxolitinib phosphate CAS:1092939-17-7 for Anticancer

CAS No.: 1092939-17-7

Pharmacy Grade

$11-13/G FOB

Alpha GPC Alpha GPC

CAS No.: 28319-77-9

pharm grade

$1/MT FOB

human relaxin 2 Relaxin H2 (human)

CAS No.: 99489-94-8

Pharmacy Grade

$1/BOU FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.